^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    10d
    TARLATEM: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Centre Leon Berard
    New P1/2 trial
    |
    temozolomide • Imdelltra (tarlatamab-dlle)
    11d
    A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov)
    P1, N=122, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Gazyva (obinutuzumab) • clesitamig (RG6524)
    13d
    MERLIN: Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Fundación GECP
    New P2 trial
    |
    Imdelltra (tarlatamab-dlle)
    14d
    Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients. (PubMed, Cancer Immunol Immunother)
    This cytokine profiling highlights the complex pathophysiology of CRS and the involvement of diverse cytokine networks beyond the IL-6 axis. These findings may guide future biomarker development, disease classification, and therapeutic strategies beyond IL-6 inhibition, advancing personalized CRS management.
    Journal
    |
    IFNG (Interferon, gamma) • HGF (Hepatocyte growth factor) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Imdelltra (tarlatamab-dlle)
    16d
    DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=269, Active, not recruiting, Amgen | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
    16d
    DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. (PubMed, JTO Clin Res Rep)
    Tarlatamab appeared effective when added to osimertinib. Further analysis of the combination of bispecific DLL3 T-cell engager and EGFR tyrosine kinase inhibitor is warranted to confirm these findings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RB1 mutation • DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tagrisso (osimertinib) • Imdelltra (tarlatamab-dlle)
    17d
    Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1 trial • Checkpoint inhibition
    |
    Hetronifly (serplulimab) • alveltamig (ZG006)
    17d
    ZG006-002: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=265, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=105 --> 265
    Enrollment change
    |
    alveltamig (ZG006)
    22d
    DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (clinicaltrials.gov)
    P1, N=55, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • etoposide IV • obrixtamig (BI 764532)
    23d
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (clinicaltrials.gov)
    P1/2, N=170, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    23d
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)